RetroSense Therapeutics to Present at the 8th Ocular Diseases Drug Discovery Conference

ByConnor Hodde

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD).  RetroSense is developing optogenetic approaches to partial vision restoration in retinitis pigmentosa and potentially dry age-related macular degeneration.

Read the entire article here.

Similar Posts

eyecro’s First Published Article in Molecular and Cellular Biology

ByConnor Hodde

Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism  Krysten M. Farjoa,#,    Rafal A. Farjob,    Stacey Halseya,    Gennadiy Moiseyeva and    Jian-xing Maa  aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…

Solving Three Major Age-related Eye Conditions in One Go

ByConnor Hodde

Vascular endothelial growth factor A (VEGF-A) is looking like more of an optical troublemaker than ever before – as well as its link with wet age-related macular degeneration (AMD), it also might be causing dry AMD and even age-related cataracts.  Therefore, Massachusetts General Hospital researcher and paper author, Dr Alexander Marneros, is looking at what processes…

EyeCRO Contributes to LUXTURNA® Potency Assay Validation

ByConnor Hodde

We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…

EyeCRO CEO Rafal Farjo Named ARVO Foundation Chair

ByConnor Hodde

We are excited to announce that our CEO, Rafal Farjo, Ph.D., has been named the ARVO Foundation for Eye Research Chair. This prestigious appointment highlights Dr. Farjo’s extensive experience and dedication to advancing ocular research over the past 25 years. As the CEO of EyeCRO, Dr. Farjo has been instrumental in helping clients develop new…

‘Positive Stress’ Helps Protect Eye from Glaucoma

ByConnor Hodde

Researchers increased the resistance of  cells to damage by repeatedly exposing the mice to low levels of oxygen similar to those found at high altitudes. The stress of the intermittent low-oxygen environment induces a protective response called tolerance that makes nerve cells — including those in the eye — less vulnerable to harm. Stress is…

Study Findings Help Design Next-Generation Nanocarriers

ByConnor Hodde

Researchers believe that atomic-scale design of pharmaceuticals will be instrumental in producing more accurate and efficient drugs. Nanocarriers are engineered particles capable of holding tiny molecules inside their hollow interiors. Antibodies, which are bonded to the outer surface of these nanocarriers, function as markers to target specific cells or tissues or supply drugs to infected…